228 related articles for article (PubMed ID: 17972922)
1. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
2. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
3. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
4. Retroviral insertion site analysis in dominant haematopoietic clones.
Kustikova OS; Modlich U; Fehse B
Methods Mol Biol; 2009; 506():373-90. PubMed ID: 19110639
[TBL] [Abstract][Full Text] [Related]
5. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for haematopoietic and lymphoid disorders.
Kohn DB
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():54-7. PubMed ID: 9020937
[TBL] [Abstract][Full Text] [Related]
7. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
8. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
[TBL] [Abstract][Full Text] [Related]
9. Insertional mutagenesis in gene therapy and stem cell biology.
Baum C
Curr Opin Hematol; 2007 Jul; 14(4):337-42. PubMed ID: 17534158
[TBL] [Abstract][Full Text] [Related]
10. Retroviral integration site analysis in hematopoietic stem cells.
Kustikova OS; Baum C; Fehse B
Methods Mol Biol; 2008; 430():255-67. PubMed ID: 18370305
[TBL] [Abstract][Full Text] [Related]
11. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
12. Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells.
Siapati EK; Bigger BW; Kashofer K; Themis M; Thrasher AJ; Bonnet D
Eur J Haematol; 2007 Apr; 78(4):303-13. PubMed ID: 17378892
[TBL] [Abstract][Full Text] [Related]
13. Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene.
Li Z; Kustikova OS; Kamino K; Neumann T; Rhein M; Grassman E; Fehse B; Baum C
Ann N Y Acad Sci; 2007 Jun; 1106():95-113. PubMed ID: 17395733
[TBL] [Abstract][Full Text] [Related]
14. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
15. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.
Romano G; Marino IR; Pentimalli F; Adamo V; Giordano A
Drug News Perspect; 2009 May; 22(4):185-96. PubMed ID: 19536363
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
18. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
19. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract][Full Text] [Related]
20. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]